Form 4: Kiniksa Pharmaceuticals Executive Eben Tessari Reports Share Transactions

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reports the disposition of shares to cover tax obligations related to vested restricted share units.

Summary

• On March 16, 2025, Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving Class A Ordinary Shares.
• Tessari disposed of 1,964 shares to satisfy tax withholding obligations related to the vesting of Restricted Share Units (RSUs).
• Additionally, 577 shares were disposed of at a price of $22.61 to cover tax obligations.
• Following these transactions, Tessari directly owns 77,953 Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: This is a neutral report on insider transactions related to tax obligations, with no inherent positive or negative implications for the company's overall outlook.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for executives to sell shares to cover tax obligations when equity awards vest.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• Similar filings are made by executives at companies like Amgen, Regeneron, and Vertex Pharmaceuticals when they exercise stock options or RSUs.
• The reporting requirements are governed by Section 16(a) of the Securities Exchange Act of 1934.

Stakeholder Impact

• The transactions have a minimal direct impact on shareholders, as they are related to tax obligations of an executive.
• The transactions do not directly affect employees, customers, suppliers, or creditors.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Eben Tessari, Class A Ordinary Shares, Restricted Share Units, RSU, Form 4, Beneficial Ownership, Insider Trading